• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Product Image

Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  • Published: February 2012
  • 76 pages
  • GlobalData

FEATURED COMPANIES

  • Ariad Pharmaceuticals
  • Merck & Co. Inc.
  • Merck Serono
  • PharmaMar S.A.
  • Threshold Pharmaceuticals
  • MORE

Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Liposarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Liposarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Liposarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Liposarcoma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Liposarcoma Therapeutics - Introduction
2.1 Disease Overview
2.1.1 Subtypes of Liposarcoma
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.5 Prognosis
2.6 Staging
2.6.1 Stage I
2.6.2 Stage II-III
2.6.3 Stage IV (metastatic)
2.7 Survival Rate
2.8 Risk Factors for Liposarcoma
2.9 Diagnosis
2.9.1 Biopsy
2.9.2 Computerized Tomography (CT) scan
2.9.3 Magnetic Resonance Imaging (MRI)
2.9.4 Positron Emission Tomography (PET) scan
2.9.5 X-ray
2.10 Treatment of Liposarcoma
2.10.1 Surgery
2.10.2 Radiation
2.10.3 Chemotherapy
2.10.4 First-line therapy (The US, Europe and Japan)
2.10.5 Second-line therapy (The US, Europe and Japan)
2.10.6 Approved second-line/ third-line therapy in Europe
2.11 GlobalData Pipeline Report Guidance
3 Liposarcoma Therapeutics - Market Characterization
3.1 Liposarcoma Therapeutics Market Size (2006-2011) - Global
3.2 Liposarcoma Therapeutics Market Forecast (2011-2019) - Global
3.3 Liposarcoma Therapeutics Market Size (2006-2011) - the US
3.4 Liposarcoma Therapeutics Market Forecast (2011-2019) - the US
3.5 Liposarcoma Therapeutics Market Size (2006-2011) - the UK
3.6 Liposarcoma Therapeutics Market Forecast (2011-2019) –the UK
3.7 Liposarcoma Therapeutics Market Size (2006-2011) - France
3.8 Liposarcoma Therapeutics Market Forecast (2011-2019) - France
3.9 Liposarcoma Therapeutics Market Size (2006-2011) - Germany
3.10 Liposarcoma Therapeutics Market Forecast (2011-2019) - Germany
3.11 Liposarcoma Therapeutics Market Size (2006-2011) - Italy
3.12 Liposarcoma Therapeutics Market Forecast (2011-2019) - Italy
3.13 Liposarcoma Therapeutics Market Size (2006-2011) - Spain
3.14 Liposarcoma Therapeutics Market Forecast (2011-2019) - Spain
3.15 Liposarcoma Therapeutics Market Size (2006-2011) - Japan
3.16 Liposarcoma Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for Liposarcoma
3.17.1 Drivers for the Liposarcoma Therapeutics Market
3.17.2 Barriers for the Liposarcoma Therapeutics Market
3.18 Opportunity and Unmet Needs
3.19 Key Takeaway
4 Liposarcoma Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Product Profiles for the Major Products in Liposarcoma
4.2.1 Yondelis (trabectedin, ET-743)
4.2.2 Doxorubicin
4.2.3 Ifosfamide
4.3 Key Takeaway
5 Liposarcoma Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Pipeline Analysis by Phase of Development
5.3.1 Liposarcoma Therapeutics - Pre- registration
5.3.2 Liposarcoma Therapeutics - Phase III Pipeline
5.3.3 Liposarcoma Therapeutics - Phase II Pipeline
5.3.4 Liposarcoma Therapeutics - Phase I/II Pipeline
5.3.5 Liposarcoma Therapeutics - Phase I Pipeline
5.4 Liposarcoma Therapeutics - Pipeline by Mechanism of Action
5.5 Liposarcoma Therapeutics - Other Promising Mechanisms of Actions
5.6 Technology Trends Analytic Framework
5.7 Liposarcoma Therapeutics– Promising Drugs under Clinical Development
5.8 Molecule Profile for Drugs under Phase III Clinical Development
5.8.1 Ridaforolimus
5.8.2 TH-302
5.9 Key Takeaway
6 Liposarcoma Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Sponsors Participating in Liposarcoma Therapeutics Clinical Trials
7 Liposarcoma Therapeutics - Strategic Assessment
7.1 Future Market Competition Scenario
8 Liposarcoma Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles for the Marketed and Promising Drugs
8.2.1 Ariad Pharmaceuticals
8.2.2 Merck & Co. Inc.
8.2.3 Johnson & Johnson Pharmaceutical Research & Development, L.L.C
8.2.4 PharmaMar S.A.
8.2.5 Threshold Pharmaceuticals
8.2.6 Merck Serono
8.3 Other Companies in the Liposarcoma Market, 2011
9 Liposarcoma Therapeutics - Licensing and Partnership Deals
10 Liposarcoma Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Recurrence in subtypes of liposarcoma
Table 2: Incidence of liposarcoma in Major Markets in 2011
Table 3: Five year survival rates for subtypes of liposarcoma
Table 4: Surgical resection in liposarcoma
Table 5: First-line therapy treatment for liposarcoma in G7
Table 6: Second-line therapy treatment for liposarcoma in G7
Table 7: Liposarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 8: Liposarcoma Therapeutics Market, Global, Market Forecast ($m), 2011-2019
Table 9: Liposarcoma Therapeutics Market, the US, Revenue($m), 2006-2011
Table 10: Liposarcoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019
Table 11: Liposarcoma Therapeutics Market, the UK, Revenue ($m), 2006-2011
Table 12: Liposarcoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019
Table 13: Liposarcoma Therapeutics Market, France, Revenue ($m), 2006-2011
Table 14: Liposarcoma Therapeutics Market, France, Market Forecast ($m), 2011-2019
Table 15: Liposarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 16: Liposarcoma Therapeutics Market, Germany, Market Forecast ($m),2011-2019
Table 17: Liposarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 18: Liposarcoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019
Table 19: Liposarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 20: Liposarcoma Therapeutics Market, Spain, Market Forecast ($m), 2011-2019
Table 21: Liposarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 22: Liposarcoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019
Table 23: Efficacy of trabectedin
Table 24: Comparison of Yondelis adverse events with doxorubicin and ifosfamide
Table 25: Liposarcoma Therapeutics - Pre-registration, 2011
Table 26: Liposarcoma Therapeutics - Phase III Pipeline, 2011
Table 27: Liposarcoma Therapeutics - Phase II Pipeline, 2011
Table 28: Liposarcoma Therapeutics - Phase I/II Pipeline, 2011
Table 29: Liposarcoma Therapeutics - Phase I Pipeline, 2011
Table 30: Liposarcoma Therapeutics - Other Promising Mechanisms of Actions
Table 31: Liposarcoam Therapeutics– Promising Drugs Under Clinical Development, 2011
Table 32: Patients characteristics in SUCCEED trial
Table 33: PFS observed in SUCCEED trial
Table 34: Adverse Events observed during SUCCEED trial
Table 35: Adverse events observed with the class of mTOR inhibitors
Table 36: Responses shown by soft tissue sarcoma group in TH-302 Phase II study
Table 37: Adverse events of TH-302
Table 38: Hematologic Toxicity shown by TH-302
Table 39: Liposarcoma Therapeutics - Clinical Mapping by Region / Country, 2011
Table 40: Liposarcoma Therapeutics - Clinical Mapping by Phase, 2011
Table 41: Liposarcoma Therapeutics - Clinical Mapping by Trial Status, 2011
Table 42: Liposarcoma Therapeutics - Clinical Mapping by Overall Sponsors, 2011
Table 43: Liposarcoma Therapeutics - Clinical Mapping by Prominent Sponsors, 2011
Table 44: Liposarcoma Therapeutics - Clinical Mapping by Top Sponsors, 2011
Table 45: Ariad Pharmaceuticals - Liposarcoma Pipeline Product, 2011
Table 46: Merck & Co. - Liposarcoma Pipeline Product, 2011
Table 47: Threshold Pharmaceuticals Inc. - Liposarcoma Pipeline Product, 2011
Table 48: Merck Serono - LiposarcomaTherapeutics Pipeline
Table 49: Liposarcoma Therapeutics - Future Players, 2011
Table 50: Liposarcoma Therapeutics, Global, Deals

1.2 List of Figures
Figure 1: Characteristics of subtypes of liposarcoma
Figure 2: Percentage split of subtypes of liposarcoma
Figure 3: Yondelis treatment pathway as second/third line therapy
Figure 4: Liposarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 5: Liposarcoma Therapeutics , Market Share (%), 2011
Figure 6: Liposarcoma Therapeutics Market, Global, Market Forecast ($m), 2011-2019
Figure 7: Liposarcoma Therapeutics, Market Share (%), 2019
Figure 8: Liposarcoma Therapeutics Market, the US, Revenue ($m), 2006-2011
Figure 9: Liposarcoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019
Figure 10: Liposarcoma Therapeutics Market, the UK, Revenue ($m), 2006-2011
Figure 11: Liposarcoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019
Figure 12: Liposarcoma Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 13: Liposarcoma Therapeutics Market, France, Market Forecast ($m), 2011-2019
Figure 14: Liposarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 15: Liposarcoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019
Figure 16: Liposarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 17: Liposarcoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019
Figure 18: Liposarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 19: Liposarcoma Therapeutics Market, Spain, Market Forecast ($m), 2011-2019
Figure 20: Liposarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 21: Liposarcoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019
Figure 22: Liposarcoma Therapeutics - Drivers and Barriers, 2011
Figure 23: Opportunity and Unmet Need in Liposarcoma Therapeutics Market, 2011
Figure 24: Strategic Competitor Assessment of Liposarcoma Therapeutics Market, 2011
Figure 25: Liposarcoma Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 26: Liposarcoma Therapeutics - Clinical Pipeline by Mechanism of Action, 2011
Figure 27: Technology Trends Analytic Framework of the Liposarcoma Therapeutics Pipeline, 2011
Figure 28: Technology Trends Analytic Framework of the Liposarcoma Therapeutics Pipeline - Description, 2011
Figure 29: Response shown by liposaroma patients in TH-302 Phase II study
Figure 30: Liposarcoma Therapeutics - Clinical Mapping by Region / Country, 2011
Figure 31: Liposarcoma Therapeutics - Clinical Mapping by Phase, 2011
Figure 32: Liposarcoma Therapeutics - Clinical Mapping by Trial Status, 2011
Figure 33: Liposarcoma Therapeutics - Clinical Mapping by Overall Sponsors, 2011
Figure 34: Liposarcoma Therapeutics - Clinical Mapping by Prominent Sponsors, 2011
Figure 35: Liposarcoma Therapeutics - Clinical Mapping by Top Sponsors, 2011
Figure 36: Liposarcoma Therapeutics - Implications for Future Market Competition, 2011
Figure 37: Liposarcoma Therapeutics - Clinical Pipeline by Company, 2011
Figure 38: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global liposarcoma market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global liposarcoma sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Liposarcoma Therapeutics Market is Forecast to Show High Growth Until 2019

GlobalData valued the global (the US, the UK, France, Germany, Italy, Spain and Japan) liposarcoma therapeutics market at $50m in 2011, and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 12.2% to reach $125m in 2019. In the European liposarcoma market there is an approved drug, Yondelis (trabectedin), which is used as a second/third line therapy for the treatment of advanced soft tissue sarcoma (including liposarcoma). The US and Japanese liposarcoma market is dominated by generic chemotherapy drugs such as doxorubicin, ifosfamide and other combinations which are used off-label. The high growth in the market is attributed to the expected launch of late stage novel pipeline drugs such as ridaforolimus in pre-registration, TH-302 in Phase III stage of development in the US, the UK, France, Germany, Italy, Spain and Japan and Yondelis in Phase III stage in the US. These targeted drug therapies with low toxicity are expected to launch in the forecast period. The entry of ridaforolimus would reduce the risk of disease progression in liposarcoma patients.

Promising Pipeline Candidates Provide Hope for the Liposarcoma Treatment Paradigm

There are currently 19 novel molecules under different stages of development in the liposarcoma pipeline. Ridaforolimus (orphan drug exclusivity and fast track status granted by the US FDA and EMEA) is in Pre-registration stage, and TH-302 is in Phase III stage of development in the US, the UK, France, Germany, Italy, Spain and Japan. The orphan drug Yondelis is in Phase III stage of development in the US. There are four company-sponsored First-In-Class (FIC) molecules in the Phase II stage of development. The launch of these molecules could provide treatment options for delaying disease progression. If launched, these novel molecules with enhanced efficacy, safety, tolerability and delayed disease progression could offer better options for patients with liposarcoma.

Ariad Pharmaceuticals
Merck & Co. Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
PharmaMar S.A.
Threshold Pharmaceuticals
Merck Serono

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos